Symbols

MOR(Delisted)

MorphoSys·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 2

Significant Revenue Decline

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MOR

Morphosys Ag

A commercial-stage biopharmaceutical company that developing innovative cancer medicines

Industry

Established Date

03/03/1998

Listing Date

04/19/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

524

Fiscal Year Ends

12-31

Website

www.morphosys.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

Semmelweisstrasse 7, 82152 Planegg, Germany

Business

Introduction

MorphoSys AG, founded on March 3, 1998, is a global biotechnology company focused on the development and commercialization of innovative cancer drugs. Based on its proprietary technology platform and leadership in therapeutic antibody discovery, power generation and engineering, the company is involved in the development of more than 100 therapeutic products with its partners. The company's extensive pipeline spans two business segments: proprietary development and collaborative discovery, and the company generates product candidates for its partners in the pharmaceutical and biotechnology industries based on the goals identified by the partners. The company currently has 28 product candidates in clinical development, including the state-of-the-art patented product candidate MOR208, for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Company Financials

EPS

MOR has released its 2023 Q3 earnings. EPS was reported at -0.95, versus the expected -1.82, beating expectations. The chart below visualizes how MOR has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

MOR has released its 2024 Q2 earnings report, with revenue of 37.11M, reflecting a YoY change of 27.93%, and net profit of -84.82M, showing a YoY change of -5.02%. The Sankey diagram below clearly presents MOR's revenue sources and cost distribution.